AcouSort AB (ACOU) AI Stock Analysis

• Market Cap: €71.11M
• Dividend Yield: N/A
• Average Volume (3M): 28.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 61.82%
• EPS Growth: 38.14%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 21,163,902
• 10 Day Avg. Volume: 39,535
• 30 Day Avg. Volume: 27,995
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

AcouSort AB's stock score is primarily hindered by its weak financial performance characterized by declining revenues and net losses. The negative valuation metrics, along with bearish technical indicators, further contribute to a low overall score. The company's lack of debt is a positive aspect but is overshadowed by operational inefficiencies and financial instability.

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB is a Swedish company that specializes in the development and commercialization of innovative acoustic-based separation technologies for the life sciences sector. The company focuses primarily on the development of products and solutions that facilitate the processing and handling of biological samples, particularly in the areas of diagnostics and cell research. AcouSort's core offerings include systems and devices that utilize acoustic forces to separate, enrich, and handle cells, particles, and biomolecules in a rapid and precise manner.

How the Company Makes Money

AcouSort AB generates revenue through the sale of its acoustic separation systems and devices to research institutions, diagnostic companies, and clinical laboratories. The company also earns income by providing custom solutions and services that leverage its proprietary technology for specific customer needs. Additionally, AcouSort may engage in partnerships and collaborations with other companies and research entities to further develop and market its technologies, which can also contribute to its revenue streams through licensing agreements or joint ventures. The company's earnings are influenced by the demand for advanced diagnostic and research tools that can offer improved efficiency and accuracy in biological sample processing.

AcouSort AB Financial Statement Overview

Summary

AcouSort AB faces financial challenges with declining revenues, consistent net losses, and negative cash flow, which could affect its long-term viability. While the lack of debt is a positive, the company's operational and profitability struggles need to be addressed.

Income Statement

The company shows a volatile revenue trajectory with a significant drop in revenue from 2023 to 2024. Gross profit margin has been inconsistent, and the company is operating at a net loss, indicating profitability challenges. The negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The equity ratio is stable, suggesting a solid capital structure with no debt, which reduces financial risk. However, the declining stockholders' equity over time and persistent net losses could pose future financial stability risks.

Cash Flow

The company experiences negative free cash flow, indicating potential cash management challenges. The operating cash flow is consistently negative, suggesting difficulties in covering operating expenses through core business activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.97M	4.74M	10.55M	4.96M	3.01M	4.93M
Gross Profit	4.96M	4.77M	8.39M	2.91M	548.00K	3.04M
EBITDA	-14.92M	-15.89M	-16.70M	-12.86M	-11.46M	-7.72M
Net Income	-15.37M	-15.08M	-17.09M	-13.21M	-12.38M	-8.22M
Balance Sheet
Total Assets	11.77M	12.32M	34.51M	42.66M	36.56M	13.17M
Cash, Cash Equivalents and Short-Term Investments	3.45M	3.57M	23.99M	33.97M	31.52M	8.12M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	6.90M	3.86M	10.38M	22.54M	3.54M	3.58M
Stockholders Equity	4.87M	8.46M	24.14M	20.11M	33.02M	9.59M
Cash Flow
Free Cash Flow	-17.14M	-19.84M	-31.77M	2.95M	-12.23M	-8.63M
Operating Cash Flow	-16.30M	-18.81M	-31.56M	3.96M	-10.92M	-7.04M
Investing Cash Flow	-888.00K	-1.02M	-1.16M	-1.01M	-1.31M	-1.59M
Financing Cash Flow	-85.00K	-157.00K	22.08M	0.00	35.63M	11.65M

AcouSort AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Neutral. The current price of 3.24 is above the 20-day moving average (MA) of 3.23, below the 50-day MA of 3.34, and below the 200-day MA of 5.69, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 80.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	44.95M	-0.99	0.00%	8.81%	-94.12%	-25.83%
MODTX	42 Neutral	59.23M	-2.64	0.00%	―	0.00%	21.80%
EXPRS2	41 Neutral	45.78M	-0.85	-55.62%	―	-13.08%	32.78%
ACOU	39 Underperform	€71.11M	―	-73.50%	―	61.82%	38.14%
SPRINT	39 Underperform	62.04M	-1.93	0.00%	―	-30.49%	-242.26%
LIDDS	37 Underperform	9.74M	-1.30	0.00%	―	0.00%	88.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%